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Abstract 
Background: Poly(alkyl cyanoacrylate) (PACA) nanoparticles have shown promise as drug carriers both to solid tumors 
and across the blood–brain barrier. Efficient drug delivery requires both high cellular uptake of the nanoparticles 
and release of the drug from the nanoparticles. Release of hydrophobic drugs from PACA nanoparticles is primarily 
governed by nanoparticle degradation, and this process has been poorly studied at the cellular level. Here we use 
the hydrophobic model drug Nile Red 668 (NR668) to investigate intracellular degradation of PACA nanoparticles by 
measuring changes in NR668 fluorescence emission and lifetime, as the spectral properties of NR668 depend on the 
hydrophobicity of the dye environment. We also assess the potential of poly(butyl cyanoacrylate) (PBCA) and poly(octyl 
cyanoacrylate) (POCA) nanoparticles for intracellular drug delivery in the prostate cancer cell line PC3 and rat brain 
endothelial cell line RBE4 and the role of endocytosis pathways in PACA nanoparticle uptake in those cell lines.
Results: Fluorescence lifetime imaging, emission spectra analysis and Förster resonance energy transfer indicated 
that the intracellular degradation was in line with the degradation found by direct methods such as gas chromatog-
raphy and scanning electron microscopy, showing that PBCA has a faster degradation rate compared to POCA. The 
combined P(BCA/OCA) nanoparticles had an intermediate degradation rate. The uptake of POCA and PBCA nano-
particles was much higher in RBE4 than in PC3 cells. Endocytosis inhibition studies showed that both clathrin- and 
caveolin-mediated endocytosis were involved in PACA nanoparticle uptake, and that the former played a predomi-
nant role, particularly in PC3 cells.
Conclusions: In the present study, we used three different optical techniques to show that within a 24-hour period 
PBCA nanoparticles degraded significantly inside cells, releasing their payload into the cytosol, while POCA nanopar-
ticles remained intact. This indicates that it is possible to tune the intracellular drug release rate by choosing appro-
priate monomers from the PACA family or by using hybrid PACA nanoparticles containing different monomers. In 
addition, we showed that the uptake of PACA nanoparticles depends not only on the monomer material, but also on 
the cell type, and that different cell lines can use different internalization pathways.
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Background
Achieving sufficient drug accumulation in the tumor 
and limiting toxicity towards healthy tissues are major 
challenges in cancer treatment [1]. One strategy is to 
encapsulate drugs into nanoparticles (NPs). Circulating 
NPs passively accumulate in some solid tumors due to 
fenestrations in tumor capillaries and lack of functional 
lymphatics, the so-called enhanced permeability and 
retention effect [2].
One of the advantages of NP-mediated drug delivery 
is the possibility of targeted, controlled and sustained 
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release of drugs. In most target organs, cellular uptake of 
NPs occurs primarily through clathrin-mediated endo-
cytosis (CME), although caveolin-mediated endocytosis 
(CavME) and other mechanisms can also play a role [3]. 
Intracellular drug release from the NPs occurs either by 
NP degradation or drug diffusion out of the NP, and can 
also be induced by external triggers such as hyperthermia 
[4], ultrasound [5] or changes in the local microenviron-
ment, for instance pH [6].
Among various nanoparticles currently investigated 
for their potential in cancer treatment, polymeric NPs 
have emerged as promising drug carriers. Their advan-
tages include easy fabrication and functionalization, 
biocompatibility, sustained drug release and controlla-
ble degradation rate [6]. Certain formulations based on 
PACA NPs have reached Phases II and III in clinical trials 
[7, 8]. Recently, we described the synthesis of poly(alkyl 
cyanoacrylate) (PACA) NPs using a one-step miniemul-
sion process [9]. These particles can be made from dif-
ferent alkyl cyanoacrylate monomers and their mixtures, 
leading to varying degradability.
Release of highly hydrophobic drugs from PACA NPs 
appears to be primarily governed by NP degradation. There-
fore, uptake profile and intracellular degradation of PACA 
NPs are the two key factors affecting intracellular drug 
availability once the NPs have reached the tumor cells. The 
uptake of NPs in cells, including PACA NPs, demonstrates 
different uptake efficacy by different cell types and organs 
[10, 11]. Degradation of PACA NPs mainly occurs by sur-
face erosion [12, 13] into water-soluble poly(cyanoacrylic 
acid) and a primary alcohol following hydrolysis of the ester 
[14]. This process can also be catalyzed by esterases [15]. 
Other proposed degradation mechanisms are probably 
less important at physiological conditions [16]. To the best 
of our knowledge, however, degradation and drug release 
for PACA NPs have been mainly studied in solution using 
physicochemical techniques [12, 17–19]. One recent study 
described the intracellular payload release from poly(butyl 
cyanoacrylate) NPs [11], but knowledge of the intracellular 
degradation of different PACA NPs remains scarce.
Thus, the aim of our work was to study the cellular 
uptake of PACA NPs and their intracellular degrada-
tion, leading to the release of a model drug. The cellular 
uptake and intracellular trafficking of PACA NPs were 
studied in two different cell lines using flow cytometry 
(FCM) and confocal laser scanning microscopy (CLSM). 
Rat brain endothelial cells (RBE4) were chosen because 
of the reported ability of PACA NPs to cross the blood 
brain barrier [20], and human prostate cancer cells (PC3) 
were chosen to assess NP uptake and degradation in a 
common human tumor cell line. Two different mono-
mers, butyl cyanoacrylate (BCA) and octyl cyanoacrylate 
(OCA), were used to produce PBCA, POCA and P(BCA/
OCA) NPs. PBCA NPs are reported to degrade faster 
than POCA, and their copolymer could potentially have a 
tunable, intermediate degradation rate that could be used 
to achieve required drug release kinetics [13].
Degradation rates under different extracellular condi-
tions were compared to intracellular model drug release. 
Nile Red 668 (NR668), a novel hydrophobic dye with the 
emission spectrum depending on the hydrophobicity of 
the local environment, was chosen due to its high hydro-
phobicity and unique spectral properties [21]. In addition, 
NR668 shows no leakage out of our PACA NPs (Additional 
file 1: Figure S1), which is required to avoid false interpreta-
tion of results based on fluorescence signals. Both its emis-
sion spectrum and fluorescence lifetime depend on the 
local environment and can be used to locate the dye intra-
cellularly. Emission spectrum analysis has previously been 
used by our group to locate Nile Red [22], while the use of 
fluorescence lifetime imaging (FLIM) to study intracellular 
degradation has, to our knowledge, only been reported for 
doxorubicin in poly(lactide-co-glycolide) NPs [23].
The three complementary optical techniques showed 
that the intracellular degradation rates of the PBCA and 
POCA NPs are in line with the rates measured in solu-
tion. In addition, we report that the uptake of PACA NPs 
depends both on the monomer material and the cell line 
used, and that different cells can use different internaliza-
tion pathways for PACA NP endocytosis.
Results
Initial NP characterization
The diameters of the three NPs were in the range of 148–
177  nm with a relatively narrow size distribution [poly-
dispersity index (PDI) ≤ 0.12]. All three NPs were slightly 
negatively charged with a zeta-potential of approximately 
−10 mV. The molecular weight of the PBCA and POCA 
NPs was approximately the same 3500 and 3700  Da, 
respectively (Table 1).
Cellular uptake of PACA nanoparticles
PBCA and POCA NP uptake kinetics in PC3 and 
RBE4 cells were measured using FCM (Fig.  1) and 













PBCA 177 0.12 −12 3500 25
POCA 151 0.10 −10 3700 48
P(BCA/OCA) 148 0.10 −9 – ∼500
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internalization was confirmed by CLSM (Fig.  2). Cel-
lular uptake is presented both as fluorescence intensity 
(Fig. 1a) and the percentage of fluorescent cells (Fig. 1b).
RBE4 cells had a significantly higher NP uptake than 
PC3 cells with more than fourfold difference after 3  h. 
After 24  h, PBCA and POCA NP uptake in RBE4 cells 
was 40 and 8 times higher, respectively, compared to 
PC3 cells. Approximately 90  % of RBE4 cells internal-
ized NPs after 1 h, whereas PC3 cells reached this level 
after approximately 24  h (Fig.  1b). The cellular uptake 
depended on the monomer. In RBE4 cells, PBCA and 
POCA NPs were initially taken up with approximately 
equal efficiency, while sixfold higher uptake of PBCA 
NPs was observed after 24  h compared to POCA NPs. 
On the other hand, in PC3 cells the uptake of POCA NPs 
was eightfold higher than PBCA NPs already after 3  h 
(Fig. 1a).
PBCA NP colocalized with early endosomes, late 
endosomes and lysosomes in RBE4 cells (Fig.  2a, b, c) 
and POCA NP colocalized with lysosomes in PC3 cells 
(Fig. 2d). Both cell lines were incubated with NPs for 3 h 
and, assuming continuous internalization, some NPs 
were expected to be found in the various endocytic com-
partments. Figure  2 shows some colocalization (white 
arrows), but many endocytic compartments contained 
no NPs, and several NPs did not colocalize with any 
endosomes or lysosomes.
Endocytosis inhibitors demonstrated that both CME 
and CavME were important uptake mechanisms (Fig. 3). 
In PC3 cells, both inhibitors reduced POCA NP uptake 
by approximately 40 %. Inhibiting CavME did not affect 
PBCA NP uptake in PC3 cells, whereas inhibiting CME 
reduced PBCA NP uptake by approximately 40 %. Endo-
cytosis inhibition in RBE4 cells had a greater effect than 
in PC3 cells as inhibition of CME and CavME reduced 
POCA NP uptake by 73 and 43  %, respectively, and 
PBCA NP uptake by 83 and 56  %, respectively. Endo-
cytosis is an energy-dependent process and is strongly 
inhibited at low temperatures [24]. Thus, the cells were 
incubated with NPs for minimum 2 h at 4 °C. Uptake was 
observed in neither PC3 nor RBE4 cells (Additional file 1: 
Figure S1).
PACA NP degradation
To study degradation in physiological relevant solutions, 
buffers at different pH as well as cell medium and human 
blood serum were used, and NP size and concentration 
were measured using Nanoparticle Tracking Analysis 
(NTA) (Fig. 4). PBCA NPs were found to degrade both in 
buffers at neutral pH, in cell medium with serum and in 
human serum.
The relative concentration of PBCA NPs decreased 
exponentially with half-lives of 144 days at pH 4, 7 days at 
pH 5.5 and 3 days at pH 7.4 (Fig. 4a). POCA NPs showed 
little sensitivity to pH. At all pH tested, the concentra-
tion decreased by only 10–20 % within the first 20 h and 
no further decrease was observed (Fig. 4b). A significant 
increase in NP diameter was observed for PBCA NPs. At 
physiological pH, the particle size increased by 20–30 % 
after 20 h, but was almost unchanged at pH 4.0 (Fig. 4c, 
d). POCA NPs, however, only expanded by 4 % at pH 7.4, 
with no changes observed at pH 4.0 (Fig. 4c, d). Both in 
cell medium and human serum, PBCA NP concentration 
decreased significantly, while POCA NP concentration 
was barely affected (Fig. 4e, f ). For both particles, a sig-
nificant increase in the initial size was observed in both 
cell media and serum, probably due to swelling and the 
formation of a protein corona (Fig. 4f, g).
More quantitative degradation experiments were per-
formed in buffers at pH 7.4 using gas chromatography 
Fig. 1 a PBCA and POCA NP uptake kinetics in PC3 and RBE4 cells expressed as fluorescence intensity relative to untreated cells on a logarithmic 
scale. b Percentage of NP-positive cells. n = 2, error bars are SD, partly within the symbols
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(GC) to measure the degradation products butanol and 
octanol. The degradation was measured as percentage 
of complete hydrolysis in glycine buffer at pH 9 (Fig. 5). 
After 48 h, 88 % degradation was found for PBCA NPs, as 
compared to only 3 % for POCA NPs, confirming much 
faster degradation of PBCA. Assuming a linear degra-
dation rate, this gives a half-life of 25  h for PBCA NPs, 
which is 33  % of what was found using NTA (Fig.  4a; 
Table  1). However, while NTA measures degradation in 
terms of NP concentration, GC measures the amount of 
degradation products. For the copolymer P(BCA/OCA), 
an intermediate rate of degradation (45  %) was found 
after 48  h. For POCA, linear regression gave a poor fit, 
but indicated a half-life of approximately 500 h.
To visualize the degradation, NPs were imaged by scan-
ning electron microscopy (SEM) after 0, 8 and 11 days of 
incubation at pH 7.4 (Fig. 6). On day 0 intact, spherical 
NPs were observed. After 8 and 11 days, the POCA NPs 
were still intact (Fig. 6d, f ) whereas no PBCA NPs were 
seen, probably due to degradation of the NPs (Fig. 6c, e).
Intracellular degradation of the NPs was studied by 
measuring the release of NR688 using the spectral prop-
erties of the dye. NR668 appeared to be strongly asso-
ciated with NPs as no cellular fluorescence was seen at 
Fig. 2 a Colocalization (white arrows) of PBCA NPs (red) with early endosomes), b late endosomes and c lysosomes (all in green) in RBE4 cells. d 
Colocalization of POCA NPs and lysosomes in PC3 cells. Both colors in the same pixel are seen as yellow. Cells were incubated with NPs for 3 h after 
labeling the endocytic compartments
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4 °C, and no diffuse cytoplasmic staining was observed in 
CLSM in agreement with [21]. Thus, any labeling of cyto-
plasmic lipid droplets or hydrophobic molecules should 
be caused by NR668 being released from degraded NPs. 
The size and distribution of lipid droplets are often visu-
ally similar to those of NPs in endosomes or lysosomes, 
and the dye location is therefore difficult to evaluate 
using CLSM [25]. FLIM and spectral analysis were used 
to study whether the dye was inside intact NPs or asso-
ciated with other hydrophobic cellular molecules. FLIM 
images of PC3 cells incubated with free NR668, PBCA 
NPs and POCA NPs are shown in Fig. 7a, b, c. The cells 
were incubated with NR668-loaded NPs or the free dye 
for 24 h before removing the dispersion and growing the 
cells for additional 5 days. The images show multiple life-
times, from approximately 2.5  ns (blue) to 4  ns (red) in 
cells incubated with the free dye (Fig. 7a) and PBCA NPs 
(Fig. 7b), whereas a narrow lifetime distribution around 
3  ns (yellow–green) was seen in cells incubated with 
POCA NPs (Fig. 7c).
To further quantify the variations in fluorescence life-
time, its distribution was measured in cells incubated 
with PBCA (Fig.  7d) or POCA NPs (Fig.  7e). In cells 
incubated with PBCA NPs, the fluorescence lifetimes 
increased significantly with time while the POCA NP 
lifetimes remained almost unchanged, indicating that 
even after 6–7  days inside the cells, POCA NPs were 
still intact while PBCA NPs were continuously degrad-
ing. However, 77  % of the change in lifetime (0.7 nsec) 
occurred already after 24–48 h. The large standard devia-
tions (SDs) for POCA NPs after 6–7 days (Fig. 7e) indi-
cate that those particles also underwent some changes. 
Figure 7d, e show the average of the long and short life-
times, and the correlation between the two lifetimes is 
found in Additional file 1: Figure S2.
The fluorescence emission spectra were recorded for 
cells incubated with both PBCA and POCA NPs for 24 h, 
and compared with those of free NR668 incubated with 
cells for 24 h as well as NPs prior to incubation (Fig. 7f, 
g). After 24  h, the emission spectrum of PBCA shifted 
to higher wavelengths and became similar to that of free 
NR668 inside cells. However, the emission spectrum of 
POCA NPs only shifted slightly towards the spectrum of 
free NR668, and was similar to the spectrum of POCA 
NPs not incubated with cells.
To confirm that the changes in fluorescence lifetime 
and emission spectra were due to dye release from the 
NPs and not changes in the environment inside the NPs, 
we used pentamer hydrogen thiophene acetic acid methyl 
ester (p-HTAM), a hydrophobic dye that forms a Förster 
resonance energy transfer (FRET) pair with NR668. PC3 
cells were incubated with POCA and PBCA NPs for 24 h 
and then grown for 3 days in medium without NPs. One 
hour prior to CLSM-imaging, the cells were stained with 
p-HTAM. p-HTAM was excited at 405 nm and detected 
in the interval of 500–540  nm (Fig.  8a, c). A FRET sig-
nal from NR668, detected at 650–710 nm was observed 
in cells incubated with PBCA NPs (Fig. 8b), but not with 
POCA NPs (Fig.  8d), demonstrating that NR668 from 




PACA NPs are promising carriers for drugs [26] and 
oligonucleotides [27] both across the blood–brain bar-
rier [28] and to cells in solid tumors [22]. Endocytosis is 
the predominant cellular uptake mechanism, although 
contradictory results have been reported. Earlier stud-
ies showed no endocytosis [29] whereas others [30, 31] 
Fig. 3 The effect of inhibition of endocytosis by genistein and chlorpromazine on the uptake of PBCA and POCA NPs in a PC3 cells and b in RBE4 
cells. Control is untreated cells. The median fluorescence intensity is expressed relative to autofluorescence. n = 2, error bars give SD
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Fig. 4 a Concentration of PBCA NPs and b POCA NPs at pH 7.4, 5.5 and 4.0. An exponential decay was fitted to the results in a. c Mean NP diameter 
at pH 7.4 and d pH4.0. Relative concentration (e, f) and mean diameter of NPs (g, h) in cell medium (e, g) and human blood serum (f, h)
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found that PACA NP uptake was an energy-depend-
ent process as no uptake occurred at 4  °C, similarly to 
the results presented here. The discrepancy could be 
explained by the production methods that have been 
shown to drastically change the interaction between cells 
and NPs [32]. The lack of cellular fluorescence at 4 °C also 
demonstrated that NR668 was not leaking out of PACA 
NPs or taken up by the cells through NP-cell contact-
mediated transfer, as reported earlier for Nile Red [25].
Endocytosis efficiency was cell type-dependent, and 
RBE4 cells originating from rat brain endothelium dem-
onstrated efficient uptake. The prostate tumor cell line 
PC3 showed a slow uptake and the amount of NPs per 
cell was 10–40 times lower than in RBE4 cells. A cell 
type-dependent uptake of NPs has previously been 
reported for gold NPs [33], chitosan NPs [34], and pol-
ystyrene NPs of various sizes [35]. In the latter work, 
approximately tenfold higher uptake of NPs was observed 
in human brain endothelial cells (HCMEC D3), as com-
pared to cervical cancer cells (HeLa) and human lung 
epithelium cells (A549). Thus, the high uptake in RBE4 
cells might be a property of brain endothelial cells, and 
in accordance with this, PACA NPs are reported to cross 
the blood–brain barrier when coated with certain poly-
ethylene glycol (PEG) surfactants [20, 36].
CME and CavME inhibition showed that both endo-
cytic pathways were active. CME seemed to be the domi-
nant mechanism, as its inhibition more strongly affected 
cellular uptake in both cell lines, especially in RBE4 cells, 
but also PBCA uptake in PC3 cells. For RBE4 cells, the 
combined inhibition effect of CME and CavME inhibitors 
exceeded 100 %, indicating poor inhibition selectivity. For 
PC3 cells, the inhibition effect was lower, with possible 
contribution of other pathways. CavME inhibition did 
not affect PBCA NP uptake in PC3 cells, showing that 
CME represents the predominant mechanism of PBCA 
NP uptake. To study intracellular trafficking further, early 
endosomes, late endosomes and lysosomes were visual-
ized, but only limited colocalization with those organelles 
was observed for both POCA and PBCA NPs. This indi-
cates that NPs may escape the endocytic pathway or that 
endocytosis was not a continuous process in the studied 
timeframe. The mechanism of possible escape from the 
endocytic pathway is unclear, but other groups have also 
observed limited colocalization with lysosomes for poly-
meric NPs [27, 37].
POCA NPs were internalized more efficiently than 
PBCA NPs in PC3 cells, whereas the opposite was true 
for RBE4 cells. Two known NP properties that deter-
mine endocytosis are size and charge [34]. Lower uptake 
with increasing NP size has been reported for CME and 
CavME [38]. The size and charge of POCA and PBCA 
NPs were not very different when measured by dynamic 
light scattering (DLS) in phosphate buffer. However, 
incubation in cell medium for several hours could change 
the NPs, especially the PBCA NPs that started degrading 
immediately upon incubation. We have seen that PBCA 
degradation starts with significant enlargement, prob-
ably due to swelling [39]. Both NPs expanded instantly 
in serum-supplemented cell medium and human serum, 
likely due to both swelling and protein corona formation 
[40]. However, the increase in size was rather small for 
both NPs and does probably not fully explain the differ-
ences in internalization.
Cationic NPs are internalized more efficiently than 
anionic NPs [34]. Surface degradation of PACA NPs 
leads to the formation of carboxylic acid, making the 
surface more hydrophilic [41, 42]. We have found that 
the NP zeta-potential decreases with time in medium, 
where PBCA NPs became more negatively charged than 
POCA NPs (unpublished results). This observation might 
explain the higher uptake of POCA NPs in PC3 cells. 
However, in RBE4 cells the PBCA NPs were internalized 
much more efficiently. Several other studies also demon-
strate a high uptake of PBCA NPs in brain endothelial 
cells [36] whereas, to our knowledge, POCA NP uptake 
by brain endothelium has not been reported. It is also 
noteworthy that RBE4 cells use both CME and CavME, 
whereas PC3 cells mainly use CME, especially for PBCA 
NPs, which may partly explain the observed differences 
between RBE4 and PC3 cells.
Degradation
NP degradation rate is crucial in terms of circulation 
time, stability, toxicity and drug release rate. The vari-
ous degradation rates of the PACA family polymers have 
Fig. 5 Degradation of PBCA, P(BCA/OCA) and POCA at pH 7.4 meas-
ured by gas chromatography. Degradation is indicated as  % hydroly-
sis of the NPs as a function of time. 100 % hydrolysis was obtained in 
glycine buffer at pH 9. n = 3, error bars give SD
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been shown to affect drug release rates [43]. Drug deliv-
ery through biodegradation enables continuous delivery, 
as opposed to burst delivery in conventional chemother-
apy. Thus, depending on the alkyl monomer chain length 
[12] and polymerization mechanism [44], PACA NPs may 
be made to continuously release the drug intracellularly 
for weeks, potentially affecting slowly proliferating or 
quiescent cancer cells. Degradation in biological media 
is influenced by pH, but also by enzymatic degradation 
from esterases [16, 17]. In order to investigate the contri-
bution of esterase-mediated degradation, esterase activity 
was monitored in serum-supplemented growth medium 
and in human serum over 96  h. No changes in esterase 
activity were observed that could explain the differences 
in PBCA and POCA NP degradation rates (Additional 
file 1: Figure S3). Esterase activity was reduced instantly 
and recovered within 24 h. Thus low degradation of NPs 
after approximately 48 h could not be attributed to loss of 
esterase activity.
In the present work, NP degradation is apparently 
required for NR668 release, as the dye is closely asso-
ciated with the polymeric network of the NP through 
Fig. 6 SEM images of PBCA (a, c, e) and POCA NPs (b, d, f) incubated at pH 7.4 for 0 days (a, b), 8 days (c, d) and 11 days (e, f)
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hydrophobic interactions. This was demonstrated by the 
correlation between the measured degradation rate of the 
NPs in physiological solutions and the release of NR688 
from the NPs measured intracellularly. After 48 h, 88 % of 
the PBCA NPs had degraded as measured with GC. Simi-
larly, 77  % of the change in fluorescence lifetime meas-
ured intracellularly had occurred at this time point. NPs 
were stable at low pH, but degraded rapidly at pH 7.4. 
The concentration of POCA NPs was still close to 80 % 
after over 300 h at pH values of 4.0–7.4. The degradation 
observed with NTA was confirmed by GC and SEM. Fur-
thermore, GC showed that the degradation rate could be 
manipulated by mixing the two monomers.
Intracellular degradation of PBCA NPs was also more 
efficient than that of POCA NPs. Release of NR668 
occurred from PBCA, but hardly from POCA NPs. This 
was demonstrated intracellularly by FLIM and by the 
spectral changes of the dye. Upon degradation, the fluo-
rescence lifetime for PBCA NPs increased towards the 
lifetime for POCA NPs. This might be because released 
Fig. 7 a–c FLIM images of PC3 cells incubated for 24 h with free NR668 (a), PBCA (b) and POCA NPs (c) before growing for additional 5 days. 
Each pixel is colored based on the average lifetime. Fluorescence lifetime distribution for PBCA (D) and POCA (E) NPs inside cells at 5, 24–48 and 
144–168 h (6–7 days). Emission spectra from PC3 cells incubated with free NR688 (green) or PBCA (f) or POCA NPs (g) after 24 h (red), or the NPs prior 
to incubation (blue). n = 5, error bars give SD
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NR668 diffuses to areas of higher hydrophobicity such 
as lipid droplets, thereby reaching lifetimes similar to 
intact POCA NPs. The emission spectra of NR668 in 
cells incubated with PBCA NPs showed that after 24  h 
the dye environment resembled that of free NR668. Fur-
thermore, colocalization with p-HTAM also indicated a 
location different from endosomes/lysosomes or inside 
NPs, because p-HTAM enters the cell passively rather 
than by endocytosis. FRET requires that the fluorescent 
molecules be in close proximity (approximately 10 nm), 
making FRET impossible with the dye still encapsulated 
in the NPs [45]. Thus, the FRET signal observed in cells 
incubated with PBCA NPs, but not in cells with POCA 
NPs demonstrated that PBCA, but not POCA NPs were 
degraded. It has also been reported by others that PACA 
NPs with longer alkyl chains degrade more slowly [46, 
47].
The bulk of our knowledge on PACA degradation 
originates from earlier physicochemical characterization 
studies [12, 17]. PACA NP-assisted drug delivery in vivo 
can also be indirectly linked to degradation rates. To the 
best of our knowledge, however, [11] remains the only 
work where the fate of PBCA nanocapsules was observed 
intracellularly using dual labeling of the nanocapsule 
Fig. 8 PC3 cells incubated with PBCA (a, b) or POCA NPs (c, d) for 24 h and grown for additional 72 h before p-HTAM staining. Excited at 405 nm 
and p-HTAM fluorescence detected at 500–540 (a, c) and FRET signal at 650–710 nm (b, d)
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shell and the cargo. That study, however, was performed 
with only one type of PACA NPs and mostly concerned 
the release and intracellular fate of the payload, while in 
the present work we studied the intracellular fate of dif-
ferent PACA nanocarriers.
Several groups have suggested pH-sensitive nanocarri-
ers for drug delivery [48], increasing the degradation rate 
at lower pH. Our results suggest an opposite mechanism 
which is consistent with other results for PBCA NPs 
[15]. The NPs remain intact at acidic pH and the drug is 
released into the cytosol after NP escape from the lysoso-
mal pathway, limiting lysosomal inactivation and exocy-
tosis of the drug or NPs. For therapeutic effect, cytosolic 
release of drugs and therapeutics is reported to be far 
superior to lysosomal release [37].
NR668 release from PACA NPs was studied using three 
different optical methods. Emission spectrum analysis 
and FRET are well-established methods used to char-
acterize free dye vs. intact NPs in tumor cells and tissue 
[22, 49]. FLIM is a novel method for studying intracel-
lular degradation and, albeit relatively time-consuming, 
shows promise for probing the microenvironment of the 
delivered dye as it is very sensitive and less dependent 
on fluorophore concentration than emission spectrum 
analysis [50]. Since fluorescence lifetime is sensitive to 
hydrophobicity and pH [51], it was found to be a well-
suited method for studying the release of the hydropho-
bic NR668 dye. Therefore, the combination of those three 
methods—emission spectrum analysis, FRET and FLIM, 
each providing complementary results,—allows recon-
structing a comprehensive picture of intracellular deg-
radation of PACA NPs and the release of a hydrophobic 
drug.
Conclusions
In the present study, we showed that the uptake of PACA 
NPs depends not only on the monomer material, but also 
on the cell type, and that different cell lines can use dif-
ferent internalization pathways. Within a 24-hour period, 
PBCA NPs degraded significantly inside cells, releas-
ing their payload into the cytosol, while POCA NPs 
remained intact. This shows that it is possible to tune 
the drug release rate by choosing appropriate monomers 
from the PACA family.
Methods
Synthesis and characterization of nanoparticles
The NPs used were either PBCA, POCA or P(BCA/
OCA). All NPs were prepared using the miniemulsion 
polymerization method as described previously [9]. An 
oil-in-water emulsion was prepared by mixing a mono-
mer oil phase with a water phase containing the non-
ionic PEG stabilizer (Brij®L23, Sigma-Aldrich, 20 mM) 
in 0.1  M HCl. The monomer phase contained either 
butyl-2-cyanoacrylate (BCA, Henkel Loctite) or octyl 
cyanoacrylate (OCA, Henkel Loctite) or a mixture of 
the two, a neutral oil as co-stabilizer (Miglyol 810N, 2 
wt  %, Cremer), a radical initiator (V65, Azobisdimetyl 
valeronitril, Wako, 0.9 wt %) and 0.2 wt % of the fluores-
cent dye NR668 (modified Nile Red, a kind gift from Dr. 
Klymchenko, University of Strasbourg). After emulsify-
ing (Branson Digital Sonifier, 60  % amplitude, 3  min), 
Jeffamin®M-2070 (a polyetheramine with a 19-unit 
PEG chain, Huntsman Corporation, 68 mM), was added 
to initiate the polymerization. The polymerization 
was carried out at room temperature overnight and at 
50 °C for 8 h to activate the radical initiator for polym-
erization of remaining internal monomer. Spontaneous 
polymerization was controlled by performing emulsi-
fication at acidic conditions (0.1 M HCl). The particles 
were rinsed by extensive dialysis against 0.001  M HCl 
using dialysis membranes with MWCO 12–14,000. The 
synthesized NPs were characterized for size, PDI and 
surface charge (zeta-potential) using electrophoretic 
and dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern Instruments) in 0.01  M phosphate buffer, pH 
7. Molecular weight (MW) analysis by size exclusion 
chromatography was provided by Innventia AB, Swe-
den. Briefly, the NPs were dissolved in tetrahydrofuran 
and run through the three columns containing Styragel 
HR4, Styragel HR2 and Styragel HR1 at 0.8 ml/min. Pol-
ystyrene standards with MW from 1000 to 350,000 was 
used for calibration.
Cell culture
Human PC3 prostate adenocarcinoma cells (CRL-1435, 
American type culture collection) were cultured at 37 °C 
and 5  % CO2 in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Life Technologies Corporation, USA) supple-
mented with 10 % fetal bovine serum (FBS).
RBE4 cells (a generous gift from Dr. Aschner, Vander-
bilt University) were cultured  on collagen at 37  °C and 
5 % CO2 in Ham’s F-10 medium supplemented with 10 % 
FBS, 300 µg/ml G418 and 1 ng/ml basic fibroblast growth 
factor (all from Life Technologies Corporation).
Incubation with NP and inhibition of endocytosis
Cells (PC3 or RBE4) were seeded in 8-well plates (Ibidi) 
at 18,500 cells/well and cultured for 3 days when study-
ing cellular uptake. NPs were added at a concentration 
of 20 µg/mL in growth medium and incubated for vari-
ous times up to 24 h before changing the growth medium 
prior to imaging. For the degradation studies, 10,000 cells 
were seeded per well, the NPs were removed after 24 h 
and the cells were grown for additional 6 days changing 
medium every other day.
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For endocytosis inhibition studies, PC3 or RBE4 cells 
were seeded in 12-well plates (Costar) at a density of 
125,000 cells/well and grown to reach the log phase. 
Chlorpromazine was used as a specific inhibitor of CME 
[3]. Genistein is traditionally used to inhibit CavME, 
although some inhibition of CME subtypes has also been 
reported [52]. Chlorpromazine and genistein were added 
at 10  µg/mL and 13.5  µg/mL, respectively, as used by 
others [53, 54]. The inhibitors were pre-incubated with 
cells for 1  h before adding a dispersion containing NPs 
at 20 μg/ml together with the inhibitor, and incubating at 
37 °C for 3 h. To achieve complete inhibition of endocy-
tosis, the cells were pre-incubated for 5 min at 4 °C before 
adding NPs and incubating the cells at 4 °C for 2 or 3 h, in 
the case of RBE4 and PC3 cells, respectively.
CLSM and cell labeling
Confocal images where obtained using a Leica SP8 CLSM 
with a 63 × 1.2 water objective. For NR668 excitation, a 
white light laser at 514 nm was used, and emission was 
detected at 580–660 nm using a photon counting hybrid 
detection system. Z-stacks of cells were obtained to ver-
ify that the NPs were intracellular.
In PC3 cells, lysosomes were stained with the pH sen-
sitive dye LysoTracker Blue (DND-22, Life Technologies) 
at 2.5 μM for 1 h and imaged using a pulsed multipho-
ton laser at 780  nm to excite the dye. In RBE4 cells 
early endosomes, late endosomes and lysosomes were 
labeled by cellular transduction using CellLight Early 
Endosomes-GFP, CellLight Late Endosomes-GFP and 
CellLight Lysosomes-GFP (Life Technologies), respec-
tively, at a concentration of 40 particles per cell 24 h prior 
to imaging. After labeling the organelles, cells were incu-
bated with NPs for 3 h before imaging.
Flow cytometry
The cells were analyzed using a flow cytometer (Gal-
lios, Beckman Coulter) exciting at 561 nm and detecting 
at 630  nm with a 30  nm bandpass filter. Prior to FCM, 
the cells were washed three times in PBS. 10,000 cells 
were included in each sample, and a dot plot of forward 
light scatter signal versus side scatter signal was used to 
establish a collection gate that excluded cell debris, dead 
cells and aggregates. The cellular uptake of NPs was esti-
mated both as the percentage of cells with NPs and as the 
amount of NPs per cell which was estimated from the 
median fluorescence intensity. To compare the uptake of 
PBCA and POCA NPs, which had different fluorescence 
intensity, a normalization factor of 1,9 (PBCA vs POCA) 
was used. This factor was found by measuring the fluo-
rescence intensity using a spectrophotometer (Infinite 
200Pro, Tecan). Thus the increase in median fluorescence 
between cells incubated with POCA NPs and the control 
cells was multiplied by this normalization factor and 
added to the autofluorescence.
Emission spectra analysis
The emission spectra were obtained using the Leica SP8 
CLSM. Intracellular NR688 was excited using a white 
light laser at 514 nm and detected in intervals of 10 nm 
from 550 to 700 nm. The intervals had an overlap of 5 nm 
resulting in 30 intervals. The spectra were normalized to 
the same maximum intensity for analysis.
Flim
FLIM was recorded using a Leica SP8 microscope 
equipped with the PicoQuant system. NR668 was excited 
by a white light laser at 514 nm, with detection at 565–
615 nm using a Single Photon Avalanche Detector. Sym-
PhoTime PicoQuant was used to record lifetimes in time 
domain. The lifetimes τi were calculated using a two-
exponential decay with the instrument response function 
E(t) that was fitted to the fluorescence decay curve:
The lifetimes were recorded until reaching a maximum 
intensity of 1000 photons/pixel. NR668 shows a two-
exponential decay, resulting in two different lifetimes 
which were averaged using the equation:
The software SymPhoTime provided by PicoQuant was 
used.
Förster resonance energy transfer (FRET)
FRET was performed to verify that NR668 was physi-
cally removed from the NPs upon degradation. The cells 
were incubated with 20 µg/mL of PBCA or POCA NPs 
for 24 h and grown for 3 days before staining for 1 h with 
1 µg/mL p-HTAM, a hydrophobic stain labeling, among 
others, lipid droplets [55]. NR668 released from the NPs 
might colocalize with p-HTAM in lipid droplets or other 
hydrophobic domains, enabling FRET. Images were 
obtained by exciting p-HTAM at 405 nm using a pulsed 
Hg-laser and detecting the FRET signal at 650–710 nm.
NP degradation in solutions
Nanoparticle tracking analysis (NTA, Nanosight LM10-
HS, Malvern Instruments) was used to determine NP 
concentration and diameter in various solutions. pH 
dependent NP degradation was studied in buffers with pH 
7.4 (0.01 M phosphate buffer), pH 5.5 and 4.0 (0.01 M ace-
tic acid). Degradation was also measured in cell medium 
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(DMEM, Life Technologies) with FBS, pH 7.5 and human 
blood serum (a kind gift from professor Asbjørn Nilsen, 
Medical Faculty, NTNU). The NPs were added to the 
buffer at 20  µg NPs/ml and incubated for up to 336  h 
(14  days) at 37  °C. For cell medium and human serum, 
NPs were added at 5 mg/ml, and further diluted to 20 µg/
ml in deionized water before NTA analysis. The buffer or 
medium were not changed during the incubation.
Gas chromatography
Particles were diluted to 0.1 mg NP/ml in 0.01 M phos-
phate buffer pH 7.4 and kept at 37 °C with slow shaking. 
At various time points, the particles were centrifuged 
using an ultracentrifuge (WX Ultra 80, Thermo Electron 
Corporation) at 30,000  rpm for 2  h. For complete deg-
radation, NPs were diluted to 0.1 mg NPs/ml in glycine 
buffer at pH 9 (0.2  M) and kept at 37  °C while shaking 
for 72 h before separation by ultracentrifugation. 3 µl of 
the internal standard n-pentane and 5 ml of diethyl ether 
were added to 5  ml of the supernatant and vortexed. 
1 ml of the organic phase was analyzed with a GC Agi-
lent 7890A equipped with a RTX-1 capillary column and 
helium as carrier gas. 1 µl of the sample was injected in 
split mode (1:5) and run isothermally at 45 °C for 3 min 
before initiating a temperature gradient of 10  °C/min 
until 200 °C. Pure butanol, pentanol and octanol samples 
were used as references.
Scanning electron microscopy
For SEM, the NP-dispersion was diluted to 50  µg/ml 
in water and one droplet was placed on a SEM sample 
holder. After water evaporation, the samples were sput-
ter-coated with a 10  nm gold layer and transferred to a 
Hitachi S-5500 at 15  kV acceleration voltage detecting 
secondary electrons.
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